Skip to Content

When Genes Come True

Pharmaceuticals: The first batch of drugs derived from genomics is on the way.
July 1, 1999

“We did it!” shouted T-shirts sported by the twenty-something technicians in the hallways of Human Genome Sciences (HGS) at a ribbon-cutting ceremony this spring. The staff at the Rockville, Md., biotech company was celebrating the opening of a $42 million manufacturing plant that marks the firm’s evolution from research startup to an aspiring drug maker.

The event is also a watershed in the emerging era of human “genomics”-the large-scale study of man’s estimated 80,000 to 100,000 genes. HGS helped kick off the commercialization of the field in 1992, when it was founded with plans to use scores of automated DNA sequencing machines to rapidly decode genes. Now, $275 million later, HGS is taking the first batch of drugs discovered via genomics methods into human testing.

Before genomics, the path to a biotech drug typically began when scientists identified the gene that coded for an important, well-studied protein, such as insulin. With the genetic recipe in hand, they could use recombinant DNA techniques to genetically engineer microbes used in large-scale manufacturing of the protein.

But finding a protein’s gene often was a painstaking enterprise that took years of effort. So, HGS and other genomics companies decided to reverse the process by decoding human DNA on a massive scale. They then could fish out genes and work forward, biochemically speaking, to discover new proteins that are involved in disease processes.

It’s a rapid-fire approach that William Haseltine, HGS’ CEO, has long said would produce a new pharmacopeia. Starting last year, the company began making good on the promise, introducing several candidates into early-stage human clinical trials, including proteins for protecting bone-marrow cells in chemotherapy patients and for facilitating wound healing.

The technology is also identifying hormones and enzymes that conventional drugs can target. Genomics is responsible for more than half the therapeutic targets that pharmaceutical giant Bristol-Myers Squibb in Princeton, N.J., now has in its sights, according to director of science and technology Ron Peppin.

A costly, uncertain road lies ahead before any blockbuster with an HGS logo appears on pharmacy shelves, however. Less than one-quarter of drugs pan out in clinical trials, a process that can easily cost more than $100 million and last a decade.

Keep Reading

Most Popular

AV2.0 autonomous vehicles adapt to unknown road conditions concept
AV2.0 autonomous vehicles adapt to unknown road conditions concept

The big new idea for making self-driving cars that can go anywhere

The mainstream approach to driverless cars is slow and difficult. These startups think going all-in on AI will get there faster.

biomass with Charm mobile unit in background
biomass with Charm mobile unit in background

Inside Charm Industrial’s big bet on corn stalks for carbon removal

The startup used plant matter and bio-oil to sequester thousands of tons of carbon. The question now is how reliable, scalable, and economical this approach will prove.

AGI is just chatter for now concept
AGI is just chatter for now concept

The hype around DeepMind’s new AI model misses what’s actually cool about it

Some worry that the chatter about these tools is doing the whole field a disservice.

images created by Google Imagen
images created by Google Imagen

The dark secret behind those cute AI-generated animal images

Google Brain has revealed its own image-making AI, called Imagen. But don't expect to see anything that isn't wholesome.

Stay connected

Illustration by Rose WongIllustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.